COVID-19 Vaccine Responses in PIDD Subjects

Description

The goal of our study is to assess the cellular immune responses of participants with antibody deficiency disease before and after immunization with SARS-CoV-2 mRNA vaccines.

Conditions

X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID, Common Variable Immunodeficiency, Primary Antibody Deficiencies, Secondary Hypogammaglobulinemia

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of our study is to assess the cellular immune responses of participants with antibody deficiency disease before and after immunization with SARS-CoV-2 mRNA vaccines.

Vaccine-induced SARS-CoV-2-specific T Cell Responses in Patients With Primary Immune Deficiency Disease

COVID-19 Vaccine Responses in PIDD Subjects

Condition
X-linked Agammaglobulinemia
Intervention / Treatment

-

Contacts and Locations

Saint Petersburg

University of South Florida, Saint Petersburg, Florida, United States, 33701

Chapel Hill

University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States, 27599

Durham

Duke University, Durham, North Carolina, United States, 27708

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Diagnosis of antibody deficiency with confirmatory lab or genetic testing
  • 2. Stable on immunoglobulin replacement therapy
  • 3. Age \>6 months and able to provide consent, or assent with parental consent if \<18 years
  • 4. Willing and able to receive the Pfizer BioNTech BNT162b2 mRNA or the Moderna mRNA-1273 vaccines

Ages Eligible for Study

6 Months to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Duke University,

John Sleasman, MD, PRINCIPAL_INVESTIGATOR, Duke University

Kristina De Paris, PhD, PRINCIPAL_INVESTIGATOR, University of North Carolina, Chapel Hill

Study Record Dates

2024-12-31